IR:NYSEIngersoll Rand Inc. Analysis
Data as of 2026-03-10 - not real-time
$86.51
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Ingersoll Rand has just delivered a fourth‑quarter earnings beat that sent the stock sharply higher, underscoring the resilience of its industrial and precision‑technology businesses. The company posted revenue that topped analyst expectations and earnings per share that exceeded consensus, reinforcing confidence in its growth trajectory. A modest dividend increase was announced, and the payout remains a tiny fraction of earnings, suggesting ample cash to sustain the distribution. The firm earned an “A List” rating from CDP for environmental stewardship, positioning it favorably amid tightening sustainability regulations. However, the stock is trading well above its discounted cash‑flow estimate and carries a price‑to‑earnings multiple that is markedly higher than the industry average, indicating a valuation premium. Technical indicators show the price sitting below its short‑term moving averages, a bearish MACD crossover, and an RSI in the lower‑mid range, hinting at short‑term downside pressure.
Despite the technical softness, the broader trend remains bullish as the price stays above the long‑term moving average and the company’s beta reflects a modestly elevated market sensitivity. Volatility has been pronounced, and trading volume has been on a downward trajectory, which could amplify price swings. The balance sheet features a sizable debt load offset by strong operating cash flow and a very low dividend payout ratio, supporting dividend sustainability but flagging leverage risk. Analysts collectively rate the stock as a buy with target prices well above the current level, driven by expectations of continued double‑digit revenue growth and expanding recurring revenue streams. The outlook for 2026 includes a modest organic order growth target and an aggressive M&A strategy that should further lift top‑line momentum. In sum, the fundamentals are solid and the near‑term catalyst is positive, yet the current price reflects a premium that may limit upside in the short run.
Despite the technical softness, the broader trend remains bullish as the price stays above the long‑term moving average and the company’s beta reflects a modestly elevated market sensitivity. Volatility has been pronounced, and trading volume has been on a downward trajectory, which could amplify price swings. The balance sheet features a sizable debt load offset by strong operating cash flow and a very low dividend payout ratio, supporting dividend sustainability but flagging leverage risk. Analysts collectively rate the stock as a buy with target prices well above the current level, driven by expectations of continued double‑digit revenue growth and expanding recurring revenue streams. The outlook for 2026 includes a modest organic order growth target and an aggressive M&A strategy that should further lift top‑line momentum. In sum, the fundamentals are solid and the near‑term catalyst is positive, yet the current price reflects a premium that may limit upside in the short run.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Recent earnings beat but bearish technical signals
- Valuation premium relative to fundamentals
- High volatility and decreasing volume
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Strong revenue growth outlook and recurring revenue expansion
- ESG leadership and favorable analyst sentiment
- Improving earnings and modest dividend increase
Long Term
> 3 yearsNeutral
Model confidence: 7/10
Key Factors
- Valuation gap versus discounted cash flow
- Elevated leverage and cyclicality of industrial sector
- Sustainable dividend but limited upside at current price
Key Metrics & Analysis
Financial Health
Revenue Growth10.10%
Profit Margin7.60%
P/E Ratio59.7
ROE5.77%
ROA5.20%
Debt/Equity50.70
P/B Ratio3.4
Op. Cash Flow$1.4B
Free Cash Flow$1.1B
Industry P/E29.5
Technical Analysis
TrendBullish
RSI36.4
Support$82.95
Resistance$100.96
MA 20$93.64
MA 50$89.61
MA 200$82.98
MACDBearish
VolumeDecreasing
Fear & Greed Index77.54
Valuation
Fair Value$47.96
Target Price$102.07
Upside/Downside17.98%
GradeOvervalued
TypeGrowth
Dividend Yield0.09%
Risk Assessment
Beta1.20
Volatility37.68%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.